Impact of Hydroxylase inhibitors on fibrosis associated with IBD

Mario Cabrero Manresa, Murtaza Tambuwala, Miguel Cavadas, Eoin Cummins, Alex Cheong, Cormac Taylor

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Fibrosis is a major complication of inflammatory bowel disease (IBD) which cannot be adequately addressed with pharmacologic therapy. In IBD the treatment of fibrosis usually requires surgical resection of colonic segments and is responsible for 75% of surgical interventions in Crohn’s disease (CD). Pharmacological inhibition of hydroxylases ameliorates inflammation in multiple models of IBD. We hypothesized that hydroxylase inhibition may also impact fibrosis in IBD. To test this, the effect of the hydroxylase inhibitor DMOG was tested using an in vivo model of IBD. Mice given 2.5% dextran sodium sulphate (DSS) in drinking water for 5 days and allowed natural recovery for 14 days, developed inflammation and fibrosis, as shown by higher inflammation score, higher submucosal collagen-I deposition and increased fibroblast infiltration through the colonic mucosa. Mice treated with intra peritoneal DMOG, exhibited less inflammation and lower collagen accumulation, as well as reduced fibroblast infiltration. To test whether this antifibrotic action was secondary to the anti-inflammatory effect or due to a direct anti fibrotic action, an in vitro model was used. Fibroblasts were treated with TGF-β1, the key mediator of healing and fibrosis. DMOG was given to the cells prior to TGF-β1, and α-smooth muscle actin (α-SMA) and collagen-I were analyzed as key fibrosis markers. Both markers were reduced by hydroxylase inhibitors in the presence of TGF-β1, suggesting a direct antifibrotic action in fibroblasts. Furthermore, this effect was related to a reduced expression of Smad-3 in human colonic fibroblast, a central effector of the TGF-β pathway. In conclusion, hydroxylase inhibition reduces fibrosis in vitro and in vivo affecting, at least in part, the TGF-β pathway. That could be a starting point to search for therapies that can ameliorate fibrosis in this and other diseases.
LanguageEnglish
Title of host publicationUnknown Host Publication
PagesLB789-LB789
Number of pages1
Volume28
Publication statusPublished - 1 Apr 2014
EventHypoxia -
Duration: 1 Apr 2014 → …

Conference

ConferenceHypoxia
Period1/04/14 → …

Fingerprint

Mixed Function Oxygenases
Inflammatory Bowel Diseases
Fibrosis
Fibroblasts
Inflammation
Collagen
Transforming Growth Factor beta
Dextran Sulfate
Transforming Growth Factor alpha
Crohn Disease
Drinking Water
Smooth Muscle
Actins
Mucous Membrane
Anti-Inflammatory Agents
Pharmacology
Therapeutics

Keywords

  • Inflammatory bowel disease
  • hydroxylases
  • fibrosis

Cite this

Cabrero Manresa, M., Tambuwala, M., Cavadas, M., Cummins, E., Cheong, A., & Taylor, C. (2014). Impact of Hydroxylase inhibitors on fibrosis associated with IBD. In Unknown Host Publication (Vol. 28, pp. LB789-LB789)
Cabrero Manresa, Mario ; Tambuwala, Murtaza ; Cavadas, Miguel ; Cummins, Eoin ; Cheong, Alex ; Taylor, Cormac. / Impact of Hydroxylase inhibitors on fibrosis associated with IBD. Unknown Host Publication. Vol. 28 2014. pp. LB789-LB789
@inproceedings{1603f0389958495c9c2a9d85aa266702,
title = "Impact of Hydroxylase inhibitors on fibrosis associated with IBD",
abstract = "Fibrosis is a major complication of inflammatory bowel disease (IBD) which cannot be adequately addressed with pharmacologic therapy. In IBD the treatment of fibrosis usually requires surgical resection of colonic segments and is responsible for 75{\%} of surgical interventions in Crohn’s disease (CD). Pharmacological inhibition of hydroxylases ameliorates inflammation in multiple models of IBD. We hypothesized that hydroxylase inhibition may also impact fibrosis in IBD. To test this, the effect of the hydroxylase inhibitor DMOG was tested using an in vivo model of IBD. Mice given 2.5{\%} dextran sodium sulphate (DSS) in drinking water for 5 days and allowed natural recovery for 14 days, developed inflammation and fibrosis, as shown by higher inflammation score, higher submucosal collagen-I deposition and increased fibroblast infiltration through the colonic mucosa. Mice treated with intra peritoneal DMOG, exhibited less inflammation and lower collagen accumulation, as well as reduced fibroblast infiltration. To test whether this antifibrotic action was secondary to the anti-inflammatory effect or due to a direct anti fibrotic action, an in vitro model was used. Fibroblasts were treated with TGF-β1, the key mediator of healing and fibrosis. DMOG was given to the cells prior to TGF-β1, and α-smooth muscle actin (α-SMA) and collagen-I were analyzed as key fibrosis markers. Both markers were reduced by hydroxylase inhibitors in the presence of TGF-β1, suggesting a direct antifibrotic action in fibroblasts. Furthermore, this effect was related to a reduced expression of Smad-3 in human colonic fibroblast, a central effector of the TGF-β pathway. In conclusion, hydroxylase inhibition reduces fibrosis in vitro and in vivo affecting, at least in part, the TGF-β pathway. That could be a starting point to search for therapies that can ameliorate fibrosis in this and other diseases.",
keywords = "Inflammatory bowel disease, hydroxylases, fibrosis",
author = "{Cabrero Manresa}, Mario and Murtaza Tambuwala and Miguel Cavadas and Eoin Cummins and Alex Cheong and Cormac Taylor",
year = "2014",
month = "4",
day = "1",
language = "English",
volume = "28",
pages = "LB789--LB789",
booktitle = "Unknown Host Publication",

}

Cabrero Manresa, M, Tambuwala, M, Cavadas, M, Cummins, E, Cheong, A & Taylor, C 2014, Impact of Hydroxylase inhibitors on fibrosis associated with IBD. in Unknown Host Publication. vol. 28, pp. LB789-LB789, Hypoxia, 1/04/14.

Impact of Hydroxylase inhibitors on fibrosis associated with IBD. / Cabrero Manresa, Mario; Tambuwala, Murtaza; Cavadas, Miguel; Cummins, Eoin; Cheong, Alex; Taylor, Cormac.

Unknown Host Publication. Vol. 28 2014. p. LB789-LB789.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Impact of Hydroxylase inhibitors on fibrosis associated with IBD

AU - Cabrero Manresa, Mario

AU - Tambuwala, Murtaza

AU - Cavadas, Miguel

AU - Cummins, Eoin

AU - Cheong, Alex

AU - Taylor, Cormac

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Fibrosis is a major complication of inflammatory bowel disease (IBD) which cannot be adequately addressed with pharmacologic therapy. In IBD the treatment of fibrosis usually requires surgical resection of colonic segments and is responsible for 75% of surgical interventions in Crohn’s disease (CD). Pharmacological inhibition of hydroxylases ameliorates inflammation in multiple models of IBD. We hypothesized that hydroxylase inhibition may also impact fibrosis in IBD. To test this, the effect of the hydroxylase inhibitor DMOG was tested using an in vivo model of IBD. Mice given 2.5% dextran sodium sulphate (DSS) in drinking water for 5 days and allowed natural recovery for 14 days, developed inflammation and fibrosis, as shown by higher inflammation score, higher submucosal collagen-I deposition and increased fibroblast infiltration through the colonic mucosa. Mice treated with intra peritoneal DMOG, exhibited less inflammation and lower collagen accumulation, as well as reduced fibroblast infiltration. To test whether this antifibrotic action was secondary to the anti-inflammatory effect or due to a direct anti fibrotic action, an in vitro model was used. Fibroblasts were treated with TGF-β1, the key mediator of healing and fibrosis. DMOG was given to the cells prior to TGF-β1, and α-smooth muscle actin (α-SMA) and collagen-I were analyzed as key fibrosis markers. Both markers were reduced by hydroxylase inhibitors in the presence of TGF-β1, suggesting a direct antifibrotic action in fibroblasts. Furthermore, this effect was related to a reduced expression of Smad-3 in human colonic fibroblast, a central effector of the TGF-β pathway. In conclusion, hydroxylase inhibition reduces fibrosis in vitro and in vivo affecting, at least in part, the TGF-β pathway. That could be a starting point to search for therapies that can ameliorate fibrosis in this and other diseases.

AB - Fibrosis is a major complication of inflammatory bowel disease (IBD) which cannot be adequately addressed with pharmacologic therapy. In IBD the treatment of fibrosis usually requires surgical resection of colonic segments and is responsible for 75% of surgical interventions in Crohn’s disease (CD). Pharmacological inhibition of hydroxylases ameliorates inflammation in multiple models of IBD. We hypothesized that hydroxylase inhibition may also impact fibrosis in IBD. To test this, the effect of the hydroxylase inhibitor DMOG was tested using an in vivo model of IBD. Mice given 2.5% dextran sodium sulphate (DSS) in drinking water for 5 days and allowed natural recovery for 14 days, developed inflammation and fibrosis, as shown by higher inflammation score, higher submucosal collagen-I deposition and increased fibroblast infiltration through the colonic mucosa. Mice treated with intra peritoneal DMOG, exhibited less inflammation and lower collagen accumulation, as well as reduced fibroblast infiltration. To test whether this antifibrotic action was secondary to the anti-inflammatory effect or due to a direct anti fibrotic action, an in vitro model was used. Fibroblasts were treated with TGF-β1, the key mediator of healing and fibrosis. DMOG was given to the cells prior to TGF-β1, and α-smooth muscle actin (α-SMA) and collagen-I were analyzed as key fibrosis markers. Both markers were reduced by hydroxylase inhibitors in the presence of TGF-β1, suggesting a direct antifibrotic action in fibroblasts. Furthermore, this effect was related to a reduced expression of Smad-3 in human colonic fibroblast, a central effector of the TGF-β pathway. In conclusion, hydroxylase inhibition reduces fibrosis in vitro and in vivo affecting, at least in part, the TGF-β pathway. That could be a starting point to search for therapies that can ameliorate fibrosis in this and other diseases.

KW - Inflammatory bowel disease

KW - hydroxylases

KW - fibrosis

M3 - Conference contribution

VL - 28

SP - LB789-LB789

BT - Unknown Host Publication

ER -

Cabrero Manresa M, Tambuwala M, Cavadas M, Cummins E, Cheong A, Taylor C. Impact of Hydroxylase inhibitors on fibrosis associated with IBD. In Unknown Host Publication. Vol. 28. 2014. p. LB789-LB789